Full Press Release Details
Supreme Court of Canada Rules in Favour of Cannabis Edibles
Kelowna, BC / June 23, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the Company ) provides the following information related to the
Supreme Court of Canada ruling in the Owen Smith case. This case was related to
the use of oils, edibles and forms of cannabis for medical use other than the
smoking of dried plant material.
On Thursday June 11, The Supreme court of Canada ruled
unanimously that the current law governing medical cannabis use in Canada is
contrary to the constitution. There are cases where alternative forms of
cannabis will be 'reasonably required' for the treatment of serious illnesses.
In our view, in those circumstances, the criminalization of access to the
treatment in question infringes liberty and security of the person."
The ruling is the final verdict following an August 2014 ruling
from the B.C. Appeal Court that also found the federal law to be contrary to the
Canadian Constitution that ensures life, liberty and security of the person .
In its ruling, the Canadian Supreme Court said that Inhaling
marihuana can present health risks and is less effective for some conditions
than administration of cannabis derivatives. Meanwhile the Health Minister in
Canada was quoted as saying that she was outraged by the Supreme Court
decision due to the lack of scientific evidence that supports the court s final
ruling. But in weighing the evidence, the Supreme Court said "the evidence amply
supports the trial judge s conclusions on the benefits of alternative forms of
marihuana treatment.
Lexaria is pleased that the Supreme Court of Canada, after
objectively weighing the evidence, decided in favour of the most current science
and knowledge in the sector. As a result of this ruling, Lexaria feels it will
be in a position to begin discussions with licensed producers at their
convenience, about utilizing the patent pending Lexaria technology with their
current client bases, for THC-infused edible products.
Lexaria s technology allows for higher bioavailability rates
for THC and for CBD than is possible without lipophilic enhancement technology.
This can allow for lower overall dosing requirements and/or higher effectiveness
in active molecule delivery. Lexaria s innovative lipid encapsulation process
allows the delivery of molecules such as THC and/or CBD without the harmful side
effects of ingestion via smoking, and should be embraced for the benefits to
Lexaria is a food sciences company focused on
the delivery of cannabinoid compounds procured from legal, agricultural hemp,
through gourmet foods based upon its proprietary infusion technologies.
legal CBD oil extracts, grown from agricultural hemp in locations where it is
legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its
patent-pending process to infuse concentrated amounts of CBD within lipids in
its tea, providing more bioactivity and comfort to the body during the
absorption process. Only ViPovaTM has this ground-breaking technology
for CBD/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition and other factors which may be identified from time to time in the
Company's public announcements and filings. There is no assurance that the
medical marijuana, CBD sector, or alternative health businesses will provide any
benefit to Lexaria, or that the Company will experience any growth through
participation in these sectors. There is no assurance that existing capital is
sufficient for the Company's needs or that it will need to attempt to raise
additional capital. There is no assurance that the potential future payments
contemplated in the Letter of Intent to sell the Burlington MMPR license
application will ever be received. There is no assurance that any planned
corporate activity, business venture, or initiative will be pursued, or if
pursued, will be successful. There is no assurance that any cannabinoid-based
product will promote, assist, or maintain any beneficial human health conditions
whatsoever. There is no assurance that the cannabinoid/lipid infusion technology
will provide any increase in bioavailability to any individual person. No
statement herein has been evaluated by the Food and Drug Administration (FDA).
ViPovaTM products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.